Who
Luke M. Beshar
Director
Company insider
Files Form 4 as: Director, Protara Therapeutics; Director, Omega Therapeutics; Director, Trillium Therapeutics; Director, Regenxbio; EVP & CFO, Nps Pharmaceuticals; Executive Vice President, Cambrex.
In numbers
- Trades disclosed
- 251
- Buys
- 4
- Sells
- 25
- Bought
- $225K
- Sold
- $19.6M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 31 Dec 2005
- Last trade
- 15 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 7 Jun 2024filed 10 Jun 2024 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,118 at $0.00 | filing |
| 7 Jun 2023filed 8 Jun 2023 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 30 Jun 2022filed 5 Jul 2022 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Bought | $31K10,000 at $3.10 | filing |
| 8 Jun 2022filed 10 Jun 2022 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —18,118 at $0.00 | filing |
| 8 Jun 2022filed 9 Jun 2022 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 14 Mar 2022filed 16 Mar 2022 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Bought | $43K10,000 at $4.25 | filing |
| 10 Mar 2022filed 14 Mar 2022 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Bought | $45K10,000 at $4.46 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —40,000 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —6,666 at $0.00 | filing |
| 17 Nov 2021filed 19 Nov 2021 | Trillium Therapeuticsoption or derivative | SEC FORM 4 Code D | —547,656.26 | filing |
| 29 Jul 2021filed 30 Jul 2021 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —52,941 at $0.00 | filing |
| 9 Jun 2021filed 10 Jun 2021 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2021filed 8 Jun 2021 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 9 Jun 2020filed 11 Jun 2020 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 29 May 2020filed 2 Jun 2020 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jan 2020filed 13 Jan 2020 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
News
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 5.3% – Here's WhyTARA · themarketsdaily.com · 15 Oct 2026Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)RGNX · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Luke M. Beshar; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.